Feed / SHC

Sotera Health Company

SHC

Healthcare · 18.28 -1.7% today

Isolated · not yet confirmedMarket checked 10 Sept, 15:35 GMT-4

Market read

Sotera Health Company's current read is isolated; its market group is not confirming.

No new filing conclusion is available. 0 of 39 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 2 directly disclosed connections are confirming.

Company-1.7% todayVolume comparison unavailable
Market group0 of 39 activeDiagnostics & Defense · unavailable
Disclosed network0 of 2 confirmingNo filing-linked name is confirming now
What would change this read
  • Net interest expense fell $6.1M in Q1 2026, primarily due to a lower variable rate on the Term Loan and a $75.0M principal paydown.

Invalidation: The isolated read changes if SHC's group or a disclosed connection begins moving with it.

Watch this read

Research brief

The story so far

Healthcare · Diagnostics & Research

No new filing conclusion is available. 0 of 39 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 2 directly disclosed connections are confirming.

Evidence that supports

No thresholded supportive filing evidence is available yet.

Evidence that challenges

No thresholded adverse filing evidence is available yet.

What would clarify the read
  • Net interest expense fell $6.1M in Q1 2026, primarily due to a lower variable rate on the Term Loan and a $75.0M principal paydown.

Company research

Understand the business, not just the ticker

As of Sep 10, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods7
Price observations326
Usable filing statements114
Verified relationships3
Evidence supporting the case
  • Latest annual revenue changed +5.7% year over year.
  • Net margin changed +2.7 percentage points in the latest annual period.
  • Foreign exchange has repeated favorable evidence across 5 filings.
  • Pricing and mix has repeated favorable evidence across 5 filings.
  • Demand and volume has repeated favorable evidence across 4 filings.
Evidence challenging the case
  • Capital investment and capacity has repeated adverse evidence across 5 filings.
  • Credit and interest rates has repeated adverse evidence across 5 filings.
Questions before a position

No credible peer-relative valuation comparison is available yet.

Longer-term price context

Price as of Sep 9, 2026

18.33
6m+30.4%12m+15.2%24m
Annual trajectory

Reported annual revenue and per-share history. This is accounting history, not a forecast.

PeriodRevenueYoYDiluted EPSShare change
2021-12-31$931.5M+13.9%$0.41+17.5%
2022-12-31$1.0B+7.8%$-0.83+0.3%
2023-12-31$1.0B+4.5%$0.18+1.1%
2024-12-31$1.1B+4.9%$0.16+0.6%
2025-12-31$1.2B+5.7%$0.27+0.5%

What management says matters

Persistent and emerging business drivers

Capital investment and capacitynegative · 5 filings
The variance was primarily driven by an increase in cash paid for capital expenditures of $41.5 million for the six months ended June 30, 2026 compared to the six months ended June 30, 2025.
10-Q · Aug 6, 2026
Credit and interest ratesnegative · 5 filings
Income tax expense for the six months ended June 30, 2025 differed from the statutory rate primarily due to the valuation allowance attributable to the limitation on the deductibility of interest expense, the impact of the foreign rate differential and curren…
10-Q · Aug 6, 2026
Foreign exchangemixed · 5 filings
Revenue growth was driven mainly by volume and mix of 18.1%, which was largely attributable to favorable Co-60 harvest schedule timing, coupled with a favorable impact from pricing of 2.7% and changes in foreign currency exchange rates.
10-Q · Aug 6, 2026
Pricing and mixpositive · 5 filings
Segment income and segment income margin decreased as a result of lower volume/mix and increases in other direct costs, partially offset by favorable pricing.
10-Q · Aug 6, 2026

Valuation discipline

Peer-relative valuation withheld

Jodie found no industry-matched filing peers suitable for a valuation comparison. It will not substitute broader financial-sector names.

Scenario scaffold

Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.

Price action

How the market is pricing the story

18.28-1.7% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:35 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for SHC. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Filing analysis

No comparable filing assessment is available yet

Jodie has not yet found a suitable current-versus-prior filing comparison for SHC. This does not mean the latest filing was neutral or immaterial.

Business ecosystem

The relationships behind SHC

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

STESTERIS plccompetitorFeb 24, 2026

Sterigenics Competition We compete globally with Applied Sterilization Technologies, a segment of STERIS plc, as well as other smaller or regional outsourced sterilization companies.

BATRAAtlanta Braves Holdings, Inc.customerFeb 24, 2026

Approximately 450 personal injury claims and 305 property devaluation claims related to the Atlanta facility, as well as a lawsuit in which employees of a sterilization customer of Sterigenics allege they were injured while working at the customer’s distribut…

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

SHC is currently a Follower in the organic co-movement group Diagnostics & Defense. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 2 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

This group is retained as the last observed read for SHC; it is not active in the latest market snapshot.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.